Novelion Therapeutics (Novelion Therapeutics) Scaled Net Operating Assets : 0.55 (As of Mar. 2019)

View and export this data going back to 1988. Start your Free Trial

What is Novelion Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Novelion Therapeutics's operating assets for the quarter that ended in Mar. 2019 was $290.2 Mil. Novelion Therapeutics's operating liabilities for the quarter that ended in Mar. 2019 was $101.6 Mil. Novelion Therapeutics's Total Assets for the quarter that ended in Dec. 2018 was $341.7 Mil. Therefore, Novelion Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2019 was 0.55.

Novelion Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Novelion Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Scaled Net Operating Assets Chart

Novelion Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Scaled Net Operating Assets

Get a 7-Day Free Trial

1.74

0.45

0.58

Novelion Therapeutics Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.59	0.58	0.61	0.66	0.55

Competitive Comparison of Novelion Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Novelion Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novelion Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's Scaled Net Operating Assets falls into.

Novelion Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Novelion Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2018 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2018 )
=	(Operating Assets (A: Dec. 2018 )	-	Operating Liabilities (A: Dec. 2018 ))	/	Total Assets (A: Dec. 2017 )
=	(296.561	-	82.083)	/	369.322
=	0.58

where

	Operating Assets		(A: Dec. 2018 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	341.715	-	45.154
=	296.561

	Operating Liabilities		(A: Dec. 2018 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	430.575	-	0	-	348.492
=	82.083

Novelion Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2019 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2019 )
=	(Operating Assets (Q: Mar. 2019 )	-	Operating Liabilities (Q: Mar. 2019 ))	/	Total Assets (Q: Dec. 2018 )
=	(290.201	-	101.616)	/	341.715
=	0.55

where

	Operating Assets		(Q: Mar. 2019 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	342.12	-	51.919
=	290.201

	Operating Liabilities		(Q: Mar. 2019 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	461.069	-	0	-	359.453
=	101.616

Novelion Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (Novelion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (OTCPK:NVLNF) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3

Website

http://www.novelion.com

Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.

Executives

Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Stonepine Capital, L.p.	10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Michael Dennis Price	officer: Chief Financial Officer
Benjamin Harshbarger	officer: See Remarks	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Mark Dipaolo	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
John J Orloff	director	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Stephen L Sabba	director	DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
Mark Corrigan	director
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Murray Stewart	officer: Executive Vice President, R&D	C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Mary T Szela	director, officer: Chief Executive Officer	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121